whitepaper

Application note: CAR T Cell Research

2
SHARES

Posted: 13 December 2019 | | No comments yet

Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.

New CAR strategies, continued improvements to T cell expansion methods, and combining adoptive cell transfer with other approaches such as immune checkpoint blockade, will be crucial moving forward. Trust our wide range of proteins, antibodies, kits, and assays to activate, expand, characterize, and functionally verify your CAR T cells.











To read this Application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Bio-Techne

Related organisations

Send this to a friend